The proteasome: a worthwhile target for the treatment of solid tumours?
about
Induction of Apoptosis in U937 Cells by Using a Combination of Bortezomib and Low-Intensity UltrasoundTargeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabNuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryosThe ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.PSMD9 expression predicts radiotherapy response in breast cancer.Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cellsCellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.The Isopeptidase Inhibitor G5 Triggers a Caspase-independent Necrotic Death in Cells Resistant to Apoptosis: A COMPARATIVE STUDY WITH THE PROTEASOME INHIBITOR BORTEZOMIBExosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins.Targeting important pathways in head and neck cancer: from the bench to the clinic.Role of apoptosis in colon cancer biology, therapy, and preventionSynergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.Dyclonine and alverine citrate enhance the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells.Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma.Development of targeted therapy for squamous cell carcinomas of the head and neck.Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs.Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-κB and the proteasome.Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.Proteomics and phosphoproteomics provide insights into the mechanism of action of a novel pyrazolo[3,4-d]pyrimidine Src inhibitor in human osteosarcoma.Small molecules in combination with conventional chemotherapeutic drugs: Light at the end of the tunnel?Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells.Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.Dysregulated expression of SKP2 and its role in hematological malignancies.A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.Proteasome inhibition prevents development of experimental dermal fibrosis.Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment.
P2860
Q30366081-17412366-B7F4-4067-9261-E1760B24106AQ33418562-615D0258-1925-44FD-8F7F-9F58B780CC2EQ33757740-458532DB-58AC-471D-ADF3-904173B603A3Q33916030-01CA6F2F-93F2-4269-B51F-5B8EE3F97928Q34301113-BA5D1907-2BFD-4FB5-B07D-BFE9D8A3408BQ34501422-706B8D31-9164-4812-B22B-F481AD22CE45Q35099053-A67AF11F-032C-46CB-B561-A0F476C686FBQ35915103-F8DEA402-4CA7-47AF-8A2B-5AC59CD0DC76Q36520182-FAF9D35C-9923-4857-8861-781A6E580C0DQ37136752-58611159-5DE3-433C-B09D-9698B04E6E92Q37212412-2D6B18E9-67F6-4142-BD54-4C7EA39CDE83Q37317000-630C739B-E3BC-4884-B380-4D28A03E9541Q37331465-7C80760A-7282-494F-867C-A744C1788D81Q37400663-9A4DEFDB-4A04-45C6-9A7E-53B7874327EDQ37532159-2138FEA9-249E-46E3-BF6B-8593B59B5A87Q37571496-3C3B4839-4BAE-4809-8E85-6977D17B02A1Q37854706-18EC577B-5D66-49B6-8DC0-29674B2FB046Q38045433-C7E70A37-C0B8-41B3-B033-C2BFC937DAD0Q38088360-280DBB81-9F40-444A-B278-08713C139F3BQ38111684-2534E33E-29D9-45C9-806F-8DD231ED2D90Q38887964-6592786F-8763-4171-AD8F-66E1B2193627Q39016719-B882E4E8-5F93-4472-B39A-BD041DFC9A5AQ39242775-F49522DF-104A-4A9A-A368-965BD57FE33BQ39820073-7523E091-800B-43B0-8DA8-F511E836938CQ39832776-75B41386-B3DA-45A4-B1AD-3BC50C6F3455Q42632400-51E5E1CA-FD2B-4A77-AA62-9C30B2E01BF3Q42776492-16649A1C-8590-41E7-8F28-705532DEADF7Q43152799-659D3B4C-2CA1-42E8-9855-F9A420E2C218Q47967824-99481648-C5B4-465C-8804-8988117FE115Q48678461-4FE2C8A5-09D5-4325-9731-902E32CDCEA4Q54564157-CE2C87DC-4B86-4632-83CF-3AF8F2A768E9Q55265735-20DC57DF-DB90-48F8-8EF1-A0BB9672835A
P2860
The proteasome: a worthwhile target for the treatment of solid tumours?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The proteasome: a worthwhile target for the treatment of solid tumours?
@ast
The proteasome: a worthwhile target for the treatment of solid tumours?
@en
type
label
The proteasome: a worthwhile target for the treatment of solid tumours?
@ast
The proteasome: a worthwhile target for the treatment of solid tumours?
@en
prefLabel
The proteasome: a worthwhile target for the treatment of solid tumours?
@ast
The proteasome: a worthwhile target for the treatment of solid tumours?
@en
P2093
P1476
The proteasome: a worthwhile target for the treatment of solid tumours?
@en
P2093
Amalia Milano
Francesco Caponigro
Rosario Vincenzo Iaffaioli
P304
P356
10.1016/J.EJCA.2007.01.038
P577
2007-03-26T00:00:00Z